Literature DB >> 4244455

C1 inactivator inhibition by plasmin.

P C Harpel.   

Abstract

Plasmin incubated with partially purified C[unk] inactivator produced a decrease in inhibitory activity which was related to the time of incubation and to the concentration of plasmin. This effect of plasmin was not influenced by the purity of the inhibitor preparations. Soybean trypsin inhibitor and tosyl arginine methyl ester (TAMe), substances which block the active enzymic center of plasmin, prevented the plasmin-induced inactivation. Double diffusion analysis of the functionally deficient, plasmin-treated C[unk] inactivator using a specific antibody, showed a reaction of identity with the untreated inhibitor. Agarose and acrylamide gel immunoelectrophoresis of a plasmin, inhibitor mixture showed the appearance of an additional precipitin band with immunologic reactivity similar to that of the untreated inhibitor. These results demonstrate that plasmin alters both the functional and immunoelectrophoretic properties of C[unk] inactivator, and that the active proteolytic site of plasmin is necessary for this interaction. Since C[unk] inactivator has been shown to inhibit several different proteolytic enzymes including C[unk], kallikrein, PF/Dil, and plasmin, this investigation provides a theoretical relationship between the fibrinolytic, kallikrein, and complement systems which may have pathophysiologic relevance to various human disease states.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4244455      PMCID: PMC322505          DOI: 10.1172/JCI106267

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  ACTION OF COMPLEMENT IN HEREDITARY ANGIONEUROTIC EDEMA: THE ROLE OF C'1-ESTERASE.

Authors:  V H DONALDSON; F S ROSEN
Journal:  J Clin Invest       Date:  1964-11       Impact factor: 14.808

2.  STUDIES ON HUMAN C'1-ESTERASE. I. PURIFICATION AND ENZYMATIC PROPERTIES.

Authors:  A L HAINES; I H LEPOW
Journal:  J Immunol       Date:  1964-03       Impact factor: 5.422

3.  INACTIVATION OF ANTIPLASMIN AND COMPLEMENT C1 IN HUMAN PLASMA RENDERED FIBRINOLYTIC BY SYNTHETIC ORGANIC COMPOUNDS.

Authors:  K N VONKAULLA
Journal:  Thromb Diath Haemorrh       Date:  1963-11-01

4.  Assay and properties of serum inhibitor of C'l-esterase.

Authors:  L R LEVY; I H LEPOW
Journal:  Proc Soc Exp Biol Med       Date:  1959 Aug-Sep

5.  Observations on a pro-esterase associated with partially purified first component of human complement (C'1).

Authors:  I H LEPOW; O D RATNOFF; F S ROSEN; L PILLEMER
Journal:  Proc Soc Exp Biol Med       Date:  1956-05

6.  The differentiation of esterase and fibrinolytic activity in human plasma euglobulin preparations.

Authors:  P Harpel
Journal:  Thromb Diath Haemorrh       Date:  1968-07-31

7.  The influence of calcium ions on the inactivation of human complement and its components by plasmin.

Authors:  I H LEPOW; L PILLEMER; O D RATNOFF
Journal:  J Exp Med       Date:  1953-09       Impact factor: 14.307

8.  INHIBITION OF beta HEMOLYTIC STREPTOCOCCI FIBRINOLYSIN BY TRYPSIN INHIBITOR (ANTIPROTEASE).

Authors:  I A Mirsky
Journal:  Science       Date:  1944-09-01       Impact factor: 47.728

9.  The conversion of C'IS to C'1 esterase by plasmin and trypsin.

Authors:  O D Ratnoff; G B Naff
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

10.  The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor.

Authors:  O D Ratnoff; J Pensky; D Ogston; G B Naff
Journal:  J Exp Med       Date:  1969-02-01       Impact factor: 14.307

View more
  10 in total

1.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

2.  Inhibition of the classical and alternative pathways by amino acids and their derivatives.

Authors:  Y Takada; Y Arimoto; H Mineda; A Takada
Journal:  Immunology       Date:  1978-03       Impact factor: 7.397

3.  Studies on the nature of heat-labile anti-complementary activity in normal human serum.

Authors:  R D Soltis; D Hasz; M J Morris; I D Wilson
Journal:  Clin Exp Immunol       Date:  1979-08       Impact factor: 4.330

Review 4.  Relationships among the complement, kinin, coagulation, and fibrinolytic systems.

Authors:  J S Sundsmo; D S Fair
Journal:  Springer Semin Immunopathol       Date:  1983

5.  Inflammatory sequences in acute pulmonary radiation injury.

Authors:  D O Slauson; F F Hahn; S A Benjamin; T L Chiffelle; R K Jones
Journal:  Am J Pathol       Date:  1976-03       Impact factor: 4.307

6.  Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.

Authors:  P C Harpel; N R Cooper
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

7.  Separation of plasma thromboplastin antecedent from kallikrein by the plasma 2 -macroglobulin, kallikrein inhibitor.

Authors:  P C Harpel
Journal:  J Clin Invest       Date:  1971-10       Impact factor: 14.808

8.  Inhibitors of kallikrein in human plasma.

Authors:  D J McConnell
Journal:  J Clin Invest       Date:  1972-07       Impact factor: 14.808

9.  Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein.

Authors:  P C Harpel
Journal:  J Exp Med       Date:  1970-08-01       Impact factor: 14.307

10.  Studies on human plasma alpha 2-macroglobulin-enzyme interactions. Evidence for proteolytic modification of the subunit chain structure.

Authors:  P C Harpel
Journal:  J Exp Med       Date:  1973-09-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.